Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis analysis

Página do item simplificado
dc.contributor.authorMiddleton, A.
dc.contributor.authorBinbrek, A. S.
dc.contributor.authorFonseca, F. A. H.
dc.contributor.authorWilpshaar, W.
dc.contributor.authorWatkins, C.
dc.contributor.authorStrandberg, T. E.
dc.contributor.institutionFowey Surg
dc.contributor.institutionRashid Hosp
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionAstraZeneca
dc.contributor.institutionUniv Helsinki
dc.date.accessioned2016-01-24T12:41:15Z
dc.date.available2016-01-24T12:41:15Z
dc.date.issued2006-06-01
dc.description.abstractBackground: There is an increasing body of evidence to support the benefits of reducing low-density lipoprotein cholesterol ( LDL- C) levels and this has been reflected in a lowering of LDL- C goals recommended by international guidelines. Therefore, there is a growing need for effective lipid-modifying therapies to optimise the achievement of these more stringent LDL- C goals.Objective: A meta-analysis of data pooled from five studies participating in the DISCOVERY ( DIrect Statin COmparison of LDL- C Values: an Evaluation of Rosuvastatin therapY) Programme was performed to compare the effect of rosuvastatin treatment with other statins in real-life clinical practice.Results: These studies included 6743 patients with hypercholesterolaemia from different ethnicities, countries and cultural environments. the meta-analysis showed that significantly more patients receiving rosuvastatin 10 mg achieved the 2003 European LDL- C goals compared with those who received atorvastatin 10 mg or simvastatin 20 mg ( p < 0.001 for both comparisons). A significantly greater proportion of patients receiving rosuvastatin 10 mg also achieved the 2003 European total cholesterol goal compared with those on atorvastatin 10 mg ( p < 0.001).Conclusions: the meta-analysis showed that rosuvastatin was more effective than comparator statins at lowering LDL- C levels and enabling patients to achieve lipid goals at recommended start doses. in addition, all statins studied were well tolerated and confirmed that rosuvastatin had a similar safety profile to other statins.en
dc.description.affiliationFowey Surg, Fowey, Cornwall, England
dc.description.affiliationRashid Hosp, Dubai, U Arab Emirates
dc.description.affiliationUniversidade Federal de São Paulo, Disciplina Cardiol, São Paulo, Brazil
dc.description.affiliationAstraZeneca, Macclesfield, Cheshire, England
dc.description.affiliationUniv Helsinki, Dept Med, FIN-00014 Helsinki, Finland
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Disciplina Cardiol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1181-1191
dc.identifierhttp://dx.doi.org/10.1185/030079906X100177
dc.identifier.citationCurrent Medical Research and Opinion. Newbury: Librapharm, v. 22, n. 6, p. 1181-1191, 2006.
dc.identifier.doi10.1185/030079906X100177
dc.identifier.issn0300-7995
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28974
dc.identifier.wosWOS:000238957300017
dc.language.isoeng
dc.publisherLibrapharm
dc.relation.ispartofCurrent Medical Research and Opinion
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectatorvastatinen
dc.subjectcardiovascular diseaseen
dc.subjectcoronary heart diseaseen
dc.subjectlow density lipoprotein cholesterol (LDL-C)en
dc.subjectmeta-analysisen
dc.subjectrosuvastatinen
dc.subjectsimvastatinen
dc.titleAchieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis analysisen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral